Дата |
---|
26.04.2024 |
25.04.2024 |
24.04.2024 |
23.04.2024 |
22.04.2024 |
19.04.2024 |
18.04.2024 |
17.04.2024 |
16.04.2024 |
15.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
1.59
|
1.88
|
1.60
|
1.56
|
1.73
|
1.59
|
|
|
82 535.41
|
272.00
|
1.40
|
1.77
|
1.61
|
1.6049
|
1.69
|
1.69
|
|
|
42 508.37
|
138.00
|
1.41
|
1.62
|
1.55
|
1.5054
|
1.7106
|
1.66
|
|
|
103 384.54
|
270.00
|
1.40
|
1.54
|
1.41
|
1.41
|
1.5178
|
1.495
|
|
|
79 679.53
|
280.00
|
1.45
|
1.55
|
1.66
|
1.376
|
1.70
|
1.445
|
|
|
141 478.27
|
419.00
|
1.31
|
1.71
|
1.7861
|
1.67
|
1.7861
|
1.69
|
|
|
113 370.98
|
310.00
|
1.68
|
1.83
|
1.69
|
1.645
|
1.815
|
1.67
|
|
|
70 084.52
|
235.00
|
1.68
|
2.00
|
1.89
|
1.68
|
1.9699
|
1.71
|
|
|
138 322.35
|
463.00
|
1.90
|
2.00
|
1.64
|
1.64
|
1.86
|
1.8185
|
|
|
84 477.09
|
496.00
|
1.64
|
1.79
|
2.00
|
1.64
|
2.00
|
1.64
|
|
|
177 124.86
|
540.00
|
Biofrontera Inc. (Biofrontera) is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions. With a focus on the fields of photodynamic therapy (PDT) and topical antibiotics, Biofrontera currently commercializes the FDA-approved flagship drug Ameluz (aminolevulinic acid hydrochloride gel, 10%) in the United States. When used in combination with PDT and Biofrontera’s BF-RhodoLED lamp, Ameluz-PDT is indicated for the treatment of actinic keratoses (AK), one of the most common precancerous skin conditions. Biofrontera also commercializes the drug Xepi (ozenoxacin cream, 1%), FDA-approved for the treatment of impetigo.
In collaboration with dermatologists, Biofrontera is fully committed to advancing treatment options and patient care.
Показать все Скрыть